Pfizer Inc. has named Kathrin U. Jansen, Ph.D., as senior vice president, vaccine research & development, and will be responsible for leading all Pfizer vaccine research and development programs, effective June 1st, 2015. Dr. Jansen will report directly to Mikael Dolsten, M.D., Ph.D., president of Worldwide Research and Development at Pfizer, and will be based in Pfizer’s Pearl River, New York research site. Dr. Jansen will succeed Dr. Emilio Emini, who has accepted a position at the Bill & Melinda Gates Foundation as the head of its HIV program.
Dr. Jansen was previously Chief Scientific Officer of Pfizer’s Vaccine Research and Early Development Research Unit. Dr. Jansen’s Pfizer career started when she joined Wyeth, now a wholly owned subsidiary of Pfizer, in 2006, where she was responsible for leading vaccine research with a focus on infectious disease targets, early development and clinical testing. Earlier in her career, Dr. Jansen served as VaxGen's Chief Scientific Officer and Senior Vice President for Research and Development and also directed a number of vaccine research efforts at Merck Research Laboratories, including the company’s novel bacterial vaccine programs. Her efforts led to the licensure of the world's first cervical cancer vaccine for the prevention of human papillomavirus infection (HPV).
Dr. Jansen will lead an organization of approximately 550 colleagues comprised of clinicians, vaccine process/analytical/and formulation development, and other laboratory scientists. Vaccine Research and Development Unit includes Vaccine Research and Early Development, Vaccine Immunotherapeutics, Vaccine Clinical Research and Vaccine Operations and High Throughput Clinical Testing. As of February 2015, Pfizer’s clinical vaccine pipeline includes five programs from Phase I through III targeting diseases caused by Staph aureus, Clostridium difficile and Meningitis B, as well as smoking cessation and asthma.
In other news, Pfizer has
Source: Pfizer (Jansen)